Cardiac procedures & devices × cardiovascular events

TrialCirculation2021

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.

Benjamin E Peterson et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2021

Randomised comparison

Probably reduced cardiovascular events

−34%−42% to −24%

9 in 100 instead of 13

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.66, 95% CI 0.58–0.76

One number in the abstract

the abstract, start to end

with placebo (hazard ratio, 0.66 [95% CI, 0.58-0.76];

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.660.58–0.76
Other lipid agentsCardiac procedures & devicesCardiovascular events
1 / 3

28 papers cite it

2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 33148016